← Back to Clinical Trials
Recruiting NCT07092761

NCT07092761 Evaluation of the Accuracy and Safety of A Novel Real-Time Continuous Glucose Monitoring System

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07092761
Status Recruiting
Phase
Sponsor Henan University of Science and Technology
Condition Type1diabetes
Study Type INTERVENTIONAL
Enrollment 82 participants
Start Date 2025-04-01
Primary Completion 2026-06-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
GS3 CGM

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 82 participants in total. It began in 2025-04-01 with a primary completion date of 2026-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study is to evaluate the accuracy and safety of a novel real-time CGM system among adult patients with type 1 diabetes mellitus with respect to YSI reference venous plasma sample measurements.

Eligibility Criteria

Inclusion Criteria: * Age ≥ 18 years * Diagonsed with T1DM or T2DM * Venous blood sampling access can be established in the forearm * Capable of independently reading instructions and complying with the clinical trial requirements * Willing to sign the Informed Consent Form (ICF) Exclusion Criteria: * Severe hypoglycemia within the past 6 month * Heart failure or hemiplegic sequelae due to prior cerebrovascular disease * Severe skin conditions at the sensor wear site * Extensive systemic skin disorders * Coagulation disorders confirmed by the investigator * Anemia or abnormal hematocrit * Blood donation within the past 6 months * Pregnancy (defined as positive urine test in women ≤55 years), lactation, or plans for pregnancy within ≤30 days * Current or recent (≤1 month) participation in other clinical trials * Planned MRI/CT scans during sensor wear * Allergy to medical adhesives or alcohol * Conditions impairing comprehension of informed consent or study procedures * Other exclusionary conditions per investigator's discretion

Contact & Investigator

Central Contact

Peng Liu

✉ peng.liu87@outlook.com

📞 0379-64811993

Principal Investigator

Hongwei Jiang

PRINCIPAL INVESTIGATOR

Henan University of Science and Technology

Frequently Asked Questions

Who can join the NCT07092761 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Type1diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07092761 currently recruiting?

Yes, NCT07092761 is actively recruiting participants. Contact the research team at peng.liu87@outlook.com for enrollment information.

Where is the NCT07092761 trial being conducted?

This trial is being conducted at Luoyang, China.

Who is sponsoring the NCT07092761 clinical trial?

NCT07092761 is sponsored by Henan University of Science and Technology. The principal investigator is Hongwei Jiang at Henan University of Science and Technology. The trial plans to enroll 82 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology